Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890784 | 1.00 | CTSK (0.62) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL10889644 | 0.88 | CTSK (0.61) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL1951088 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL3825684 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL627379 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL2159319 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL905289 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL16710011 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL12189206 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL629960 | 0.86 | CTSS (0.67) | CTSKCTSSPSENENCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9913851-B2 | Compositions and methods for increasing telomerase activity | TELOMERASE ACTIVATION SCIENCES, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20160318973-A1 | COMPOSITIONS AND METHODS FOR INCREASING TELOMERASE ACTIVITY | GERON CORPORATION | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318973-A1 | COMPOSITIONS AND METHODS FOR INCREASING TELOMERASE ACTIVITY | TERT, POT1, TERF2 | CTSK 1879/4885CTSS 1572/4885PSENEN 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.